I have held ISX, sold, and still follow them with a view to reentering.
I do find the reporting a bit ingenuous though. The whole three page narrative never talks about revenue or costs. When they refer to guidance, they just say "have provided market guidance". That doesn't instill much confidence that they can't even repeat it.
Ultimately its all about profit and cash generation. To avoid those topics is concerning.
I am not down ramping (albeit that i may buy at lower prices) but just calling it out for what its is.
All that being said, they do seem to be making a lot of inroads, getting the right approvals and making technical progress.
- Forums
- ASX - By Stock
- SP1
- Ann: Appendix 4E - Preliminary Report
Ann: Appendix 4E - Preliminary Report, page-6
Featured News
Add SP1 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online